Canavan Disease and the ASPA Gene: Inheritance, Carrier Testing, and Where the New Gene Therapies Stand

Canavan Disease and the ASPA Gene: Inheritance, Carrier Testing, and Where the New Gene Therapies Stand

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Research is clear that a single ASPA variant makes you a healthy carrier, not a patient. Studies report you cannot develop Canavan disease from one variant. A child is only at risk if both parents carry a pathogenic ASPA variant, and even then each pregnancy carries a 25% chance. As of 2026, no gene therapy is approved by the FDA or Health Canada, though several are in early trials.

What you’ll learn

• Why one ASPA variant means you are a carrier, not a patient, and how the disease is actually inherited.
• What a direct-to-consumer carrier result does and does not tell you, in plain numbers.
• Where the headline gene therapies really stand, and why “investigational” matters.
• The concrete next steps to take before you try to conceive, in the US and Canada.

How Canavan Disease Is Inherited: The ASPA Gene and NAA

Canavan disease is caused by changes in a gene called ASPA on chromosome 17. This gene builds an enzyme named aspartoacylase. That enzyme breaks down a brain chemical called N-acetylaspartate, or NAA.

When the enzyme is missing, NAA builds up. Think of a drain that stops working. The sink overflows. In the brain, this overflow damages myelin, the insulation around nerve fibers.

The result is a “spongy” degeneration of the brain’s white matter. This is why Canavan is called a leukodystrophy, a disease of the brain’s white matter. The ASPA gene sits on chromosome 17, at a spot labeled 17p13.2. Its job is small but essential, and losing it has large effects on the developing brain.

The link between the enzyme and the chemical is well established. A foundational study found a profound loss of aspartoacylase activity in cells from patients, along with markedly high NAA in urine and blood. That work fixed NAA as the disease’s biochemical hallmark and explained why the chemical piles up when the enzyme fails.

Canavan follows autosomal-recessive inheritance. That means a person needs two changed copies of ASPA, one from each parent, to have the disease. Picture a two-key safe that only opens, in the harmful sense, when both keys are turned. One changed copy makes you an unaffected carrier with no symptoms. Carriers are common and healthy, and most never know until a test reveals it.

The high NAA level is also a chemical fingerprint. It separates Canavan from other leukodystrophies like Krabbe disease or metachromatic leukodystrophy, which a worried reader may confuse with it. Those conditions damage myelin too, but they do not share the same NAA signature, so the biochemistry helps doctors tell them apart.

If your report flags one ASPA variant, a genetic counselor can confirm what it means for you (find one at NSGC.org). A counselor can also explain how the gene, the enzyme, and the NAA buildup connect for your specific result.

Section recap: Canavan disease comes from two changed ASPA copies, which let brain chemical NAA build up and damage myelin. One copy makes you a healthy carrier.

Risk Magnitude: What a Carrier Result Really Means

A carrier finding sounds scary, but the numbers are reassuring for you personally. Being a carrier of one ASPA variant does not put you at any risk of developing Canavan disease.

Reproductive risk is different, and it depends on your partner. Risk to a future child only appears if both partners carry a pathogenic ASPA variant. When both partners are carriers, each pregnancy has these odds:

• 25% chance (25 out of 100) of an affected child with two variants.
• 50% chance (50 out of 100) of a healthy, unaffected carrier with one variant.
• 25% chance (25 out of 100) of a child who carries no variant at all.

These odds reset with each pregnancy, like a fresh coin toss, so one outcome does not change the next.

Just as important is the flip side of those numbers. If only one partner carries a pathogenic variant, no child can have Canavan disease at all. The child may become a healthy carrier, but that is not the disease. This is why a carrier who learns the news often feels relief once the partner’s status is clear.

Carrier frequency is not the same everywhere. In the Ashkenazi Jewish population, about 1 in 40 people carry an ASPA variant, driven mainly by two founder variants named p.Glu285Ala and p.Tyr231Ter. These two variants account for roughly 98% of the changed genes seen in Ashkenazi Jewish patients. In non-Ashkenazi families, the picture is more varied, with a wider spread of rarer changes, including one called p.Ala305Glu.

To put the disease itself in perspective, it is rare even where carriers are more common. Canavan disease affects roughly 1 in 6,400 to 1 in 13,500 people of Ashkenazi heritage, and it is rarer still in the general population. So a carrier result is far more common than the disease, and most carriers never have an affected child.

One caution matters for the numbers. Direct-to-consumer panels usually test only the common Ashkenazi founder variants. So a “no variant detected” result does not fully rule out carrier status, especially for people of non-Ashkenazi ancestry. Think of it as a spelling test that only checks a handful of words; passing it does not mean every word is spelled right.

Before drawing conclusions from any percentage, ask a genetic counselor to translate the odds for your own family and ancestry.

Section recap: One ASPA variant carries zero personal disease risk. A child faces a 25 out of 100 risk only when both parents carry a pathogenic variant.

Testing Options in the US and Canada

A 23andMe or AncestryDNA carrier report is a screening tool, not a diagnosis. These panels usually check only the common Ashkenazi founder variants. They can miss carriers of other ancestries.

Clinical testing is more complete. The diagnostic hallmark of Canavan disease is markedly high NAA in urine, confirmed by high NAA on brain MR spectroscopy, a scan that measures brain chemicals. Doctors confirm the diagnosis with ASPA gene sequencing, and historically with a low enzyme-activity test. So a diagnosis rests on several layers, not a single number.

There is a useful contrast between screening and diagnosis. Screening asks a broad “could this be present?” question across many people. Diagnosis asks a precise “is this present in this person?” question and uses NAA testing, imaging, and sequencing together. A DTC report lives on the screening side, which is why it cannot stand alone.

For carriers planning a family, expanded carrier panels and full ASPA sequencing are offered by clinical labs such as Invitae and GeneDx. Professional guidelines now recommend offering carrier screening for conditions like Canavan to all patients planning a pregnancy, regardless of ethnicity. This guidance covers a large panel of recessive and X-linked conditions and was designed to move beyond ethnicity-based testing toward equal, pan-ethnic screening.

One important gap: Canavan disease is not on the US Recommended Uniform Screening Panel. It is not part of routine newborn screening in the US or Canada. It is usually found through carrier screening, family history, or symptoms, not at birth. This matters because a healthy pregnancy today does not mean the topic was already checked; it usually was not.

A quick analogy helps. A DTC report is like a smoke detector that only listens for one kind of alarm. It is useful, but a full inspection checks the whole house. Full ASPA sequencing and expanded panels do that broader check, and they are the appropriate confirmatory step. Any DTC result should be confirmed in a CLIA-certified US lab or an accredited Canadian lab before you make any reproductive or medical decision. A genetic counselor can order the right confirmatory test for you.

Section recap: DTC reports screen for a few common variants and are not diagnostic. Confirm any result with clinical NAA testing and ASPA sequencing in an accredited lab before deciding anything.

Interpreting Your Result: Diagnosis, Carrier, or VUS

Think of test results as a ladder with three rungs:

• Diagnosis: two pathogenic ASPA variants, plus high NAA and matching brain findings.
• Healthy carrier: one pathogenic variant with no symptoms.
• Variant of uncertain significance (VUS): a change whose link to disease is not yet established.

A VUS must not be treated as a diagnosis. Guidelines state it should not, by itself, drive any medical or reproductive decision. It is like a word you cannot find in the dictionary yet; you do not act on a definition you do not have.

The classification system behind these labels is standardized. Clinical labs use a five-tier framework: pathogenic, likely pathogenic, VUS, likely benign, and benign. Where a variant lands depends on the weight of evidence, and a VUS can be reclassified up or down as more data appears. So a VUS today is not a verdict; it is a “pending” file.

A single-gene DTC report cannot, on its own, tell carrier status apart from affected status. The common Ashkenazi founder variants are well studied and classified as pathogenic. Rarer or newly seen ASPA changes may stay VUS until more evidence arrives. This is one more reason a consumer label should never be the final word.

Genotype gives some clues about severity. The classic infantile form is the most common and most severe, and it typically brings a large head, low then high muscle tone, poor head control, and developmental regression. Milder or later-onset forms are rare and harder to predict. Still, prognosis should come from specialists, not from a consumer label, because the same gene can produce a range of outcomes.

There is also a practical difference between what a lab reports and what it means for you. A pathogenic label reflects strong, published evidence, while a VUS reflects a gap in evidence, not a hidden danger. Reclassification can go either way over time as databases grow, which is why counselors sometimes suggest checking back on an uncertain result in the future. This is normal science at work, not a sign that something was missed.

If your report shows a VUS or anything ambiguous, an NSGC-certified genetic counselor and a metabolic specialist can resolve it. Do not act on an unclear result alone.

Section recap: Two pathogenic variants mean a diagnosis; one means a carrier; a VUS means “unknown, do not act on it.” Ambiguous findings need a genetic counselor and specialist.

Prevention, Early Detection, and Family Management

You cannot change an inherited ASPA genotype. So the useful levers are reproductive planning, early diagnosis, and good supportive care.

For two-carrier couples, several neutral options exist:

• Preconception counseling: reviewing risk and choices before pregnancy.
• Partner carrier testing: confirming whether both partners carry a pathogenic variant.
• Preimplantation genetic testing for monogenic disease (PGT-M): screening embryos before pregnancy.
• Prenatal diagnosis: chorionic villus sampling or amniocentesis using ASPA sequencing or NAA measurement during a pregnancy.

Prenatal enzyme and NAA testing has a long track record, with early work showing it was possible in amniotic cells and chorionic villi. Guidelines frame these as non-directive choices, not recommendations to make. The goal of counseling is to lay out options clearly, not to steer any one decision.

Each option has its own timing. Partner testing and preconception counseling happen before pregnancy, which gives couples the widest set of choices. PGT-M works with in vitro fertilization, so embryos are checked before a pregnancy begins. Prenatal diagnosis by chorionic villus sampling or amniocentesis happens during a pregnancy already underway. A genetic counselor can walk through what each path involves, and none is presented as the “right” one.

If you are simply a carrier, there is nothing to monitor. Carriers need no medical surveillance and no lifestyle restriction. This is worth repeating because the disease’s severity in children can make a carrier fear for their own health without cause. The screening and planning steps are about future children, not about the carrier’s own body.

For diagnosed children, the current standard remains supportive and coordinated by a team, though the treatment section below covers the newer investigational research in detail. The key point here is that no lifestyle change or supplement in a carrier alters the underlying genetics.

For at-risk couples, expanded or Ashkenazi-panel carrier screening before pregnancy is the single most useful early step. A genetic counselor can help you choose the right panel and timing.

Section recap: Genes cannot be changed, so plan reproductively and screen early. Carriers need no monitoring; a diagnosed child needs supportive team care that eases symptoms only.

The Treatment Landscape: Supportive Care and Investigational Gene Therapies

Here is the honest picture. As of 2026, there is no FDA- or Health Canada-approved disease-modifying therapy for Canavan disease. Standard care remains supportive and multidisciplinary, and there is no established disease-modifying cure. Headlines about gene therapy can blur this line, so it is worth stating plainly before any details.

What supportive care looks like today is a coordinated team. It manages feeding and nutrition, seizures, spasticity, and breathing support, usually through a metabolic or leukodystrophy center. Physical therapy helps with muscle tone and comfort, and nutrition support helps with feeding difficulties. This care eases symptoms and improves comfort, but it does not stop the underlying disease. That limit is exactly what the new research aims to change.

It also helps to understand the disease this care responds to. The classic infantile form usually appears in the first months of life. Signs include an unusually large head, weak muscle tone that later turns to stiffness, poor head control, and a loss of skills over time. Milder and later-onset forms exist but are far rarer and less predictable. Knowing this helps a worried carrier separate their own healthy status from the severe childhood picture. Online searches tend to surface that picture first, which can frighten a person who is actually healthy.

The big change is that gene-therapy programs moved into the clinic between 2023 and 2025. One program is Myrtelle’s rAAV-Olig001-ASPA. It uses a harmless virus, called AAV, to deliver a working ASPA gene to specific brain cells, given as a single dose. It is being tested in a first-in-human Phase 1/2 trial, registered as NCT04833907.

This candidate holds FDA Regenerative Medicine Advanced Therapy, or RMAT, and Fast Track designations, granted in 2024, plus Orphan Drug and Rare Pediatric Disease status. These are expedited-development labels. They speed up the review process, but they are not marketing approvals, and no Canavan therapy is approved. In simple terms, they mean “watched closely and moving faster,” not “cleared for sale.”

Interim results in eight children were published in a peer-reviewed journal in 2025. Studies report reduced NAA in spinal fluid and some developmental gains against historical comparisons. However, 7 of 8 children, about 88 out of 100, had at least one serious adverse event, though none were judged related to the therapy. The authors call the results interim and stress they do not establish long-term safety or benefit.

A separate program is BridgeBio and Aspa Therapeutics’ BBP-812. It is an intravenous AAV9-based gene therapy, given through a vein rather than into the brain, and evaluated in the CANaspire Phase 1/2 study registered as NCT04998396. Its main measures include safety over the first year and changes in NAA in urine and in the brain, tracked by MR spectroscopy. Early biomarker data such as reduced NAA have been reported, and BBP-812 received an RMAT designation based on the CANaspire data. It is investigational and recruiting, not approved or available outside the trial. The two programs differ in delivery: one goes into the brain, the other into a vein, and both are still being studied.

The two investigational programs compare like this:

Program	Route	Sponsor	FDA designation	Trial ID	Status
rAAV-Olig001-ASPA	Into the brain (oligodendrocyte-targeted)	Myrtelle	RMAT, Fast Track, Orphan Drug, Rare Pediatric Disease	NCT04833907	Phase 1/2, investigational, not approved
BBP-812	Intravenous (AAV9, through a vein)	BridgeBio / Aspa Therapeutics	RMAT	NCT04998396 (CANaspire)	Phase 1/2, investigational, recruiting, not approved

Two cautions are vital. Early-phase results are encouraging but do not establish long-term safety or benefit. Biomarkers like NAA can move before anyone knows whether daily life improves and stays improved. And no therapy reverses brain injury that has already happened. That is why timing and early diagnosis are so heavily discussed in this field. Earlier academic ASPA gene-therapy work from the early 2000s laid groundwork but never became an approved product. Trial participation and treatment choices belong to specialists, so ask a metabolic or leukodystrophy clinician what fits your family before acting on any headline.

Section recap: No Canavan therapy is approved as of 2026. Two AAV gene therapies are in early trials with encouraging but unproven results, and neither reverses existing brain damage; a specialist should guide any decision.

Family Implications and Cascade Testing

When one relative has a confirmed pathogenic ASPA variant, testing can spread outward in a planned way. This is called cascade testing. First-degree relatives such as siblings, parents, and children may benefit from targeted carrier testing.

For reproductive risk, one test outranks all others. Because a child’s risk depends on both parents carrying a variant, your partner’s carrier status is the single most important test to pursue before or during pregnancy planning. A targeted single-variant test for a known family variant is inexpensive and definitive. Once a family’s exact variant is known, checking a relative for that one change is fast and clear.

Cascade testing works like ripples from a stone in a pond. It starts with the person who tested positive, then reaches the people most likely to share the variant. Siblings each have a chance of carrying the same variant, and testing them can clarify their own future family planning. A genetic counselor decides the order and scope that makes sense for each family.

Raising this with family can feel awkward. It helps to explain that a carrier result is common, harmless to the carrier, and simply useful information for planning. Framing it as a shared family fact, not a personal flaw, eases the conversation. Many people find that relatives are grateful to learn something actionable before their own pregnancies.

The relevance is especially high for Ashkenazi Jewish families, where founder-variant carrier frequency is about 1 in 40. Expanded Ashkenazi carrier panels are widely offered and often recommended before pregnancy.

NSGC-certified genetic counselors coordinate cascade testing, interpret family-specific results, and support these conversations. Ask one to map out who in your family may want testing.

Section recap: A partner’s carrier test is the decisive one for reproductive risk; siblings may also benefit, especially in Ashkenazi Jewish families. A genetic counselor can coordinate cascade testing.

Psychosocial Impact and US/Canada Legal Protections

A genetic result can bring real anxiety, from family-disclosure stress to worry about insurance and the potential cost of a future therapy. These concerns are valid and worth addressing directly.

In the US, the Genetic Information Nondiscrimination Act, or GINA, passed in 2008. Reinforced by the Affordable Care Act, it bars health insurers and employers from using genetic information to discriminate. But GINA has a gap. It does not cover life insurance, disability insurance, or long-term-care insurance. Once a result is on record, that gap can matter, so many people speak with a genetic counselor about timing before applying for such policies.

Canada offers broader protection. The Genetic Non-Discrimination Act of 2017 makes it a crime to require genetic testing or the disclosure of results as a condition of a service or contract, including insurance. The Supreme Court of Canada upheld this law as constitutional in 2020. So the Canadian rules reach further than the US ones, since they are not limited to health insurance and employment.

The practical takeaway differs by country. A reader in the US may want to weigh the life and disability insurance gap before putting a result on record. A reader in Canada has stronger legal cover across services and contracts. Neither rule should stop needed medical testing; the point is to plan the sequence thoughtfully, ideally with a genetic counselor who knows the local landscape.

Cost is another worry. Any future approved gene therapy would likely be a high-cost specialty product. Families may navigate access through private insurance, manufacturer or foundation support, and Medicaid or Medicare in the US, or through provincial drug programs and case-by-case rare-disease funding in Canada. Patient-advocacy groups such as the Canavan Foundation and the United Leukodystrophy Foundation offer support and community. These groups can also point families toward trials and toward others who have walked the same road.

The emotional weight is real even for a healthy carrier. Learning that a relative may have died young of an unexplained brain condition can turn a statistic into something personal. It can help to name that feeling and to bring it to a counselor rather than carry it alone. Anxiety about a future pregnancy, guilt about passing on a variant, and stress about telling family are all common reactions. None of them reflect a health problem in the carrier, and a counselor can help put them in context.

Genetic counseling also helps with the emotional side, not just the technical one. A genetic counselor can talk through disclosure, insurance timing, and coping resources with you, and connect you with the metabolic or leukodystrophy specialists who handle clinical decisions.

Section recap: GINA protects US health insurance and jobs but not life, disability, or long-term-care coverage; Canada’s law is broader. A genetic counselor can help with insurance timing, cost navigation, and the emotional load.

Frequently Asked Questions

Will I get Canavan disease if I carry one ASPA variant? No. Research is clear that one variant makes you a healthy, unaffected carrier. Canavan disease is autosomal-recessive, so it takes two changed copies, one from each parent, to cause disease. You have no symptoms and no risk of developing the disease from a single variant, and you need no medical monitoring. The severe childhood illness that shows up in online searches describes affected children with two variants, not carriers like you. Still, confirm your report’s meaning with a genetic counselor before drawing conclusions.

Will my children inherit Canavan disease? Only if your partner also carries a pathogenic ASPA variant. If both of you do, each pregnancy has a 25% chance, or 25 out of 100, of an affected child. There is also a 50% chance of a healthy carrier and a 25% chance of a child with no variant. If only one of you carries a variant, no child can have the disease, though a child can still be a healthy carrier. Each pregnancy is an independent event, so prior outcomes do not shift the odds. Partner testing gives you the real answer for your family.

Will this affect my health, life, or disability insurance? In the US, GINA and the ACA protect health insurance and employment, but not life, disability, or long-term-care insurance. That last gap is why a result on record can still matter for those specific policies. In Canada, the Genetic Non-Discrimination Act gives broader protection across services and contracts, including insurance. Because rules differ by country and policy type, ask a genetic counselor about timing before you apply for coverage that GINA does not reach.

Can my employer find out about my genetic result? In the US, GINA bars employers from requesting or using genetic information to discriminate against you. In Canada, the Genetic Non-Discrimination Act makes it a crime to require testing or disclosure as a condition of a contract. The Supreme Court of Canada upheld that law as constitutional in 2020. These protections differ in scope, so a genetic counselor or the relevant government agency can clarify what applies to your specific situation and workplace.

Should I get a second opinion or clinical confirmation? Yes, for any decision. A direct-to-consumer report is screening, not a diagnosis, and it usually checks only a few common variants. Any result should be confirmed in a CLIA-certified US lab or an accredited Canadian lab before you act on it. An NSGC-certified genetic counselor and a metabolic or leukodystrophy specialist can confirm results, order the right follow-up tests, and guide your next steps.

Summary

A single ASPA variant makes you a healthy carrier, not a patient, and you face no personal risk of Canavan disease. A future child is at risk only if your partner also carries a pathogenic variant, and even then the chance is 25 out of 100 per pregnancy. That is why partner testing is the most useful next step before conceiving.

Direct-to-consumer panels screen for a few common variants and are not diagnostic, so any result needs clinical confirmation. On treatment, be clear-eyed. As of 2026 no gene therapy is approved by the FDA or Health Canada. Myrtelle’s rAAV-Olig001-ASPA (NCT04833907) and BridgeBio/Aspa’s BBP-812 (CANaspire, NCT04998396) are both in early trials. These are investigational, and no therapy reverses existing brain damage.

The calm, concrete path forward is to see an NSGC-certified genetic counselor, arrange partner and clinical testing, and let metabolic or leukodystrophy specialists guide any medical decision. None of these steps needs to be rushed, and taking them in order turns a frightening report into a clear, manageable plan. A counselor can help you sequence them in the way that fits your family and your timeline.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. OMIM #271900 (Johns Hopkins University). CANAVAN DISEASE; CAN — Online Mendelian Inheritance in Man Entry #271900. https://omim.org/entry/271900
2. MedlinePlus Genetics (U.S. National Library of Medicine / NIH). Canavan disease — condition summary. https://medlineplus.gov/genetics/condition/canavan-disease/
3. Matalon R & Michals-Matalon K. Canavan Disease — GeneReviews (NCBI Bookshelf, University of Washington). https://www.ncbi.nlm.nih.gov/books/NBK1234/
4. Matalon R, Michals K, Sebesta D, et al. (1988). Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. American Journal of Medical Genetics 29:463-471. https://pubmed.ncbi.nlm.nih.gov/3354621/
5. Gregg AR, Aarabi M, Klugman S, et al.; ACMG (2021). Screening for autosomal recessive and X-linked conditions during pregnancy and preconception. Genetics in Medicine 23:1793-1806. https://www.nature.com/articles/s41436-021-01203-z
6. Richards S, Aziz N, Bale S, et al.; ACMG/AMP (2015). Standards and guidelines for the interpretation of sequence variants. Genetics in Medicine 17:405-424. https://pubmed.ncbi.nlm.nih.gov/25741868/
7. Feigenbaum A, Moore R, Clarke J, et al. (2004). Canavan disease: carrier-frequency determination in the Ashkenazi Jewish population. American Journal of Medical Genetics Part A 124A:142-147. https://pubmed.ncbi.nlm.nih.gov/14699612/
8. ClinicalTrials.gov NCT04998396 (Aspa Therapeutics / BridgeBio), CANaspire — A Phase 1/2 Study of AAV9 Gene Therapy (BBP-812) for Canavan Disease. https://clinicaltrials.gov/study/NCT04998396
9. ClinicalTrials.gov NCT04833907 (Myrtelle Inc.). Phase 1/2 Study of AVASPA (rAAV-Olig001-ASPA) Gene Therapy for Children With Typical Canavan Disease. https://clinicaltrials.gov/study/NCT04833907
10. Leone P, Lober RM, Francis J, et al. (2025). Oligodendrocyte-targeted adeno-associated virus gene therapy for Canavan disease in children: a phase 1/2 trial. Nature Medicine. https://www.nature.com/articles/s41591-025-03919-w
11. Myrtelle, Inc. / PR Newswire (April 2024). rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives RMAT Designation from the U.S. FDA. https://myrtellegtx.com/
12. U.S. EEOC / U.S. Congress. Genetic Information Nondiscrimination Act (GINA) of 2008 — EEOC guidance. https://www.eeoc.gov/statutes/genetic-information-nondiscrimination-act-2008
13. Supreme Court of Canada. Reference re Genetic Non-Discrimination Act, 2020 SCC 17 (Genetic Non-Discrimination Act, S.C. 2017, c. 3). https://www.scc-csc.ca/case-dossier/cb/2020/38478-eng.aspx

Last updated: 2026-08-04

Author: Genelumen editorial team. This article aggregates 13 sources from peer-reviewed medical literature and public health agencies (tier 1=10 / tier 2=1), including NIH/OMIM/MedlinePlus, PubMed-indexed publications, ClinicalTrials.gov, ACMG and NSGC guidelines, EEOC/GINA guidance, and the Supreme Court of Canada.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Image: Editorial illustration.

Related: Genetic Diseases category

🌐 日本語版: カナバン病の遺伝と保因者